RxDoctor Payments Data

Michele Lee, MD

Cornea and External Diseases Specialist · Scottsdale, AZNPI 1396164299

Payments from drug & device makers

$7,459in general payments, 2019–2025

Across 190 payments — averaging $39.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$2K
  • Alcon$1K
  • Bausch & Lomb Americas Inc.$879
  • Sun Pharmaceutical Industries Inc.$504
  • Dompe US, Inc.$425
  • AbbVie$420
  • plus $2K from 20 others

What the payments were for

  • Speaking & faculty fees$320%
  • Food & beverage$7,427100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cornea and external diseases specialist providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$726,210
Medicare patients
1,638
Services billed
5,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj21$923,983
RestasisCyclosporine80$94,223
XiidraLifitegrast54$76,990
Prednisolone Acetate383$20,578
LumiganBimatoprost34$20,406
Cyclosporine45$16,499
Fluorometholone128$12,978
LotemaxLoteprednol Etabonate18$9,318
MoxifloxacinMoxifloxacin Hcl270$6,276
Dorzolamide-TimololDorzolamide/Timolol/Pf11$2,911
TafluprostTafluprost/Pf14$2,514
Ketorolac Tromethamine67$2,473
Latanoprost251$2,427
ValacyclovirValacyclovir Hcl29$1,601
Timolol Maleate76$1,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$425$923,98321 claims
AbbVieRestasis, Lumigan$420$114,628114 claims
Bausch & Lomb Americas Inc.Xiidra$879$76,99054 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other cornea and external diseases specialist in Scottsdale

Where these figures come from

Is this you, or does something look wrong? →